Sulbactam/Ampicillin: In Vitro Spectrum, Potency, and Activity in Models of Acute Infection
James A. Retsema(Pfizer (United States)), Perry S. Sawyer(Pfizer (United States)), A. R. English(Pfizer (United States)), John E. Lynch(Pfizer (United States)), Agnès Girard(Pfizer (United States)), J. A. Faiella(Pfizer (United States)), L. A. Brennan(Pfizer (United States)), MARGARET R. ANDERSON(Pfizer (United States)), C. R. Cimochowski(Pfizer (United States)), W. Norcia(Pfizer (United States))
Cited by 106
Related Papers
Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms
|Antimicrobial Agents and Chemotherapy|1987|461
CP-45,899, a Beta-Lactamase Inhibitor That Extends the Antibacterial Spectrum of Beta-Lactams: Initial Bacteriological Characterization
|Antimicrobial Agents and Chemotherapy|1978|397
<b>Molecular cloning and functional analysis of a novel macrolide‐resistance determinant, <i>mefA</i>, from <i>Streptococcus pyogenes</i></b>
|Molecular Microbiology|1996|360
Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution
|Antimicrobial Agents and Chemotherapy|1987|323